Deuterium-Depleted Water

1. What conditions has Deuterium-Depleted Water been studied for?

• Cancer (preclinical and limited clinical): Multiple in vitro and in vivo experiments across cancer models; one interventional/clinical study in lung cancer patients; studies also include breast cancer mouse models (4T1, MCF-7) and lung cancer cell work (e.g., A549 cells).

• Depression / affective-disorder related outcomes: Epidemiologic correlation (US regions) plus mouse chronic stress model assessing depressive-like behavior, hippocampal serotonin transporter (SERT), neurogenesis, and sleep EEG.

• Diabetes / glucose metabolism: Human study in 30 volunteers with pre- or manifest diabetes; additional mention of observations in oncologic patients with diabetes and rat studies.

• Neuroprotection / hypoxia / oxidative stress in nervous tissue: Neuronal culture under glucose deprivation; rat brain oxidative stress markers and learning under hypoxia.

• Sepsis-related liver injury (animal model): Rat cecal ligation and puncture (CLP) model evaluating liver histology, oxidative stress and inflammatory parameters.

• Cognition / long-term memory (animal): Mentioned in a broad review as “enhancing long-term memory in rats.”

• “Anti-aging,” lipid metabolism, metabolic syndrome, obesity-related outcomes, anti-inflammatory and detoxification claims: These are described in broad narrative/scoping reviews as areas of interest, but the studies reviewed here do not detail specific controlled human trials for these endpoints.

• Sports performance: Mentioned in the scoping review as a condition/outcome area studied, without details in the study text.

2. Does it work in treating those conditions? Summarize the evidence.

• Cancer

  • Systematic review (2008–2023): Included 15 studies (14 preclinical; 1 interventional). It concluded DDW alone or combined with chemotherapy inhibited cancer progression in “most experiments,” and that combination therapy appeared more effective than chemotherapy alone in those experiments. Mechanistic emphasis was on ROS-related genes and the Keap1–Nrf2 pathway, but the review explicitly calls for more extensive randomized controlled trials.

  • Clinical lung cancer study (129 patients): Patients consumed DDW in addition to conventional chemo/radiotherapy. Reported median survival times (MST) of 25.9 months (males) and 74.1 months (females), with a statistically significant gender difference (p<0.05), and 5-year survival probabilities of 19% (males) and 52% (females). However, the study does not describe randomization, blinding, or a contemporaneous control group, so causality and magnitude of benefit are uncertain from the study alone.

  • Mechanistic cell study (A549): Proteomics/thermal profiling suggested mitochondrial involvement and increased oxidative stress (ROS), with slower growth and possible apoptosis. Notably, the study also reports a potential feedback/adaptation: “further deuterium depletion” triggered restoration of redox equilibrium and resumed growth, implying effects may be dose- and context-dependent.

  • Mouse breast cancer models (DDW and deuterium-depleted yolk): In 4T1 and MCF-7 models, treated groups had smaller tumor volume in lungs and improved outcomes versus controls; adding deuterium-depleted yolk appeared to enhance the anticancer effect versus DDW alone in that study.

• Depression / depressive-like behavior

  • Epidemiology: A geographic correlation was reported between tap-water deuterium content and depression prevalence across US regions. Correlation does not establish causation and can be confounded by many regional factors.

  • Mouse chronic stress model: Two-week DDW (91 ppm) reduced depressive-like features; predator stress–suppressed dentate gyrus proliferation was attenuated with DDW. DDW also altered sleep EEG (increased wakefulness indices, decreased REM duration) in a pattern the authors note resembles SSRI effects. These are promising but remain animal data.

• Diabetes / glucose metabolism

  • Human 90-day study (n=30; 1.5 L/day; 104 ppm vs ~145 ppm): Results were mixed/heterogeneous. In 15 subjects fasting insulin and glucose decreased and insulin response improved; in the other 15, changes were in the opposite direction. Peripheral glucose disposal improved in 11 subjects. This suggests possible benefit in a subset, but inconsistent response overall and limited sample size.

• Neuroprotection / hypoxia

  • In vitro neurons: Lower deuterium in incubation medium increased survival of cultured neurons under glucose deprivation.

  • Rats under hypoxia: Pre-lowering brain deuterium prevented development of oxidative stress markers in nervous tissue and preserved learning performance in a T-maze at control levels. These findings are preclinical and do not establish human clinical efficacy.

• Sepsis-related liver injury (rats)

  • In CLP sepsis rats, DDW (15 or 30 ppm) alone or with an essential oil improved oxidative stress/antioxidant parameters (e.g., lipid peroxidation, GSH-related measures) and inflammatory parameters (e.g., prostaglandin E2, COX-2), with histologic improvement in liver injury. This is animal evidence only.

Overall, the strongest “works/doesn’t work” conclusions cannot be made from these studies alone because much of the evidence is preclinical, and the human evidence described is limited and/or not clearly randomized and controlled.

3. What health benefits does it have?

• Potential anticancer/adjuvant effects

  • Preclinical studies and a systematic review suggest DDW can inhibit tumor progression and may enhance chemotherapy effects in experimental settings.

  • Mechanistic work suggests DDW can modulate mitochondrial function and oxidative stress (ROS), potentially contributing to slowed cancer cell growth and apoptosis in some contexts.

• Potential mood-related benefits (preclinical) and geographic association

  • In mice, DDW reduced depressive-like behavior after chronic stress and attenuated stress-related reductions in dentate gyrus proliferation; sleep EEG changes were described as SSRI-like.

  • A geographic correlation was reported between tap-water deuterium content and depression prevalence (hypothesis-generating, not proof).

• Potential metabolic effects (inconsistent human data)

  • In a 90-day study in people with pre/manifest diabetes, about half showed improvements in fasting glucose/insulin and insulin response; others worsened, indicating possible benefit in a subset but not reliably across participants.

• Potential neuroprotective/anti-oxidative stress effects (animal/in vitro)

  • Improved neuronal survival under glucose deprivation in vitro.

  • In rats, prevention of hypoxia-associated oxidative stress and preservation of learning performance.

• Potential anti-inflammatory/organ-protective effects in sepsis model (animal)

  • Improved liver oxidative stress and inflammatory markers and reduced histologic injury in CLP sepsis rats.

Important limitation: many “benefits” listed in narrative/scoping reviews (e.g., anti-aging, sports performance, detoxification) are not substantiated with detailed controlled human outcomes in the studies reviewed here, so they should be considered preliminary.

4. Does it have any downsides or side effects?

• Human safety/tolerability reporting is limited in these studies: The lung cancer clinical abstract describes DDW as “nontoxic,” but does not provide adverse event rates or systematic safety monitoring details.

• Variable metabolic response: In the 30-person diabetes study, outcomes split roughly in half (15 improved, 15 worsened for fasting insulin/glucose trends). While not necessarily “side effects,” this suggests DDW may not be uniformly beneficial and could be counterproductive for some individuals, at least regarding glycemic markers.

• Potential for dose/context-dependent biological effects: The A549 cell study reports DDW-induced oxidative stress that can slow growth and induce apoptosis, but also notes that “further deuterium depletion” triggered a feedback mechanism restoring redox equilibrium and resumed growth. This implies that effects may not be linear with greater depletion and could vary by dose, duration, and cellular context.

• Sleep architecture changes (animal): In naïve mice, DDW increased EEG indices of wakefulness and decreased REM sleep duration. Whether this is beneficial or adverse depends on context and is not established in humans.

Because robust randomized controlled human safety datasets are not described in these studies, definitive statements about side effects, contraindications, pregnancy safety, kidney effects, electrolyte effects, or drug interactions cannot be made from this evidence alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

• No direct pharmacogenomic evidence is provided in these studies: None of the included studies report outcomes stratified by human genotype or specific genetic variants (e.g., polymorphisms in antioxidant response genes, serotonin transporter variants, etc.).

• Mechanistic pathways mentioned could plausibly interact with genetic variation, but this is speculative

  • Keap1–Nrf2 signaling (cancer systematic review): Because DDW effects are discussed in relation to ROS-related genes and Keap1/Nrf2 pathways, variants affecting oxidative stress responses could theoretically influence response, but no genotype-response data are presented.

  • Serotonergic mechanisms (depression mouse study): The study reports changes in hippocampal SERT and SSRI-like sleep EEG changes, suggesting serotonin-related biology; however, no genetic stratification (e.g., SLC6A4 variants) is reported.

  • Oncogene expression (lung cancer abstract): DDW attenuated DMBA-induced expression of Bcl2, Kras, and Myc in mouse lung (not human pharmacogenomics). The clinical abstract speculates benefit “especially for women with tumors overexpressing cancer-related genes,” but this is not the same as demonstrating genotype-specific benefit.

Conclusion for pharmacogenomics: based on these studies, there is insufficient evidence to claim DDW is beneficial or harmful for specific genetic variants; future trials would need genotype/biomarker stratification to address this.

References

1. Deuterium-Depleted Water in Cancer Therapy: A Systematic Review of Clinical and Experimental Trials.
   Yutong Lu, Hongping Chen (2024) - Nutrients
2. Nutritional deuterium depletion and health: a scoping review.
   Nicole Korchinsky, Anne M Davis, László G Boros (2024) - Metabolomics : Official journal of the Metabolomic Society
3. The biological impact of deuterium and therapeutic potential of deuterium-depleted water.
   Jiao Qu, Yufei Xu, Shuang Zhao, Ling Xiong, Jing Jing, Su Lui, Juan Huang, Hubing Shi (2024) - Frontiers in pharmacology
4. Deuterium content of water increases depression susceptibility: the potential role of a serotonin-related mechanism.
   Tatyana Strekalova, Matthew Evans, Anton Chernopiatko, Yvonne Couch, João Costa-Nunes, Raymond Cespuglio, Lesley Chesson, Julie Vignisse, Harry W Steinbusch, Daniel C Anthony, Igor Pomytkin, Klaus-Peter Lesch (2015) - Behavioural brain research
5. Anticancer Effect of Deuterium Depleted Water - Redox Disbalance Leads to Oxidative Stress.
   Xuepei Zhang, Massimiliano Gaetani, Alexey Chernobrovkin, Roman A Zubarev (2019) - Molecular & cellular proteomics : MCP
6. Deuterium Content of the Organic Compounds in Food Has an Impact on Tumor Growth in Mice.
   Gábor Somlyai, Lajos I Nagy, László G Puskás, András Papp, Beáta Z Kovács, István Fórizs, György Czuppon, Ildikó Somlyai (2022) - Current issues in molecular biology
7. Neuroprotective Effects of Deuterium-Depleted Water (DDW) Against H
   Yongfu Wu, Dongyun Qin, Huiling Yang, Wenya Wang, Jifei Xiao, Le Zhou, Hui Fu (2020) - Neurochemical research
8. Deuterium depleted water effects on survival of lung cancer patients and expression of Kras, Bcl2, and Myc genes in mouse lung.
   Zoltán Gyöngyi, Ferenc Budán, István Szabó, István Ember, István Kiss, Krisztina Krempels, Ildikó Somlyai, Gábor Somlyai (2013) - Nutrition and cancer
9. Effect of Systemic Subnormal Deuterium Level on Metabolic Syndrome Related and other Blood Parameters in Humans: A Preliminary Study.
   Gábor Somlyai, Ildikó Somlyai, István Fórizs, György Czuppon, András Papp, Miklós Molnár (2020) - Molecules (Basel, Switzerland)
10. Anti-inflammatory Effects of Deuterium-Depleted Water Plus
    Faezeh Fatemi, Abbas Golbodagh, Reza Hojihosseini, Abolfazl Dadkhah, Kambiz Akbarzadeh, Salome Dini, Mohammad Reza Mohammadi Malayeri (2020) - Turkish journal of pharmaceutical sciences
11. Reduction of Deuterium Level Supports Resistance of Neurons to Glucose Deprivation and Hypoxia: Study in Cultures of Neurons and on Animals.
    Alexandr Kravtsov, Stanislav Kozin, Alexandr Basov, Elena Butina, Mikhail Baryshev, Vadim Malyshko, Arkady Moiseev, Anna Elkina, Stepan Dzhimak (2021) - Molecules (Basel, Switzerland)
12. Deuterium-Depleted Water as Adjuvant Therapeutic Agent for Treatment of Diet-Induced Obesity in Rats.
    Tetiana Halenova, Igor Zlatskiy, Anton Syroeshkin, Tatiana Maximova, Tatiana Pleteneva (2019) - Molecules (Basel, Switzerland)
13. Anti-aging effects of deuterium depletion on Mn-induced toxicity in a C. elegans model.
    Daiana Silva Avila, Gábor Somlyai, Ildikó Somlyai, Michael Aschner (2012) - Toxicology letters
14. Nafion: A Flexible Template for Selective Structuring.
    Nikolai F Bunkin, Polina N Bolotskova, Sergey V Gudkov, Minh T Khuong, Valeriy A Kozlov, Svetlana L Timchenko, Valeriy V Voronov, Yulia V Novakovskaya (2024) - Polymers
15. Short term deuterium depletion in drinking water reduced tumor induced oxidative stress in mice liver.
    Bertan Boran Bayrak, Gonul Yenidogan Kulak, Refiye Yanardag, Aysen Yarat (2022) - Pathology, research and practice
16. Deuterium Depleted Water Inhibits the Proliferation of Human MCF7 Breast Cancer Cell Lines by Inducing Cell Cycle Arrest.
    Kamal Yavari, Lida Kooshesh (2019) - Nutrition and cancer
17. Deuterium-depleted water stimulates GLUT4 translocation in the presence of insulin, which leads to decreased blood glucose concentration.
    Miklós Molnár, Katalin Horváth, Tamás Dankó, Ildikó Somlyai, Beáta Zs Kovács, Gábor Somlyai (2021) - Molecular and cellular biochemistry
18. The effect of the deuterium depleted water on the biological activity of the eukaryotic cells.
    A V Syroeshkin, N V Antipova, A V Zlatska, I A Zlatskiy, M D Skylska, T V Grebennikova, V V Goncharuk (2018) - Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
19. Synergistic anticancer effects of crocin combined with deuterium-depleted water on HT-29 cells.
    Reza Haseli, Masoud Honarvar, Kamal Yavari, Mehrdad Ghavami (2023) - Anti-cancer drugs
20. Effect of deuterium-depleted water on selected cardiometabolic parameters in fructose-treated rats.
    R Rehakova, J Klimentova, M Cebova, A Barta, Z Matuskova, P Labas, O Pechanova (2016) - Physiological research

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.